drugset
drugset / Trial / NCT01636128

Urinary Biomarker Study With Sulindac and Difluoromethylornithine

NCT01636128 ↗

Phase 2 Withdrawn Cancer Prevention Pharmaceuticals, Inc. University of Arizona · collab
RandomizedCrossoverOpen-labelDiagnostic

Summary

The purpose of this study is to determine the effects of 2 drugs (sulindac and Difluoromethylornithine (DFMO)) either alone or in combination on biomarkers found in urine.

Timeline

Start
2014-03
Primary completion
2016-03
Completion
2016-04

Outcome

Outcome not reported

Stopped (Business): “Funding and staffing”

Drugs

EvaluationDrugModalityDoseRoute
Subject Difluoromethylornithine Unknown 500 mg Oral
Subject Sulindac Small molecule 150 mg Oral

Indications

No indication recorded.